Medtronic Financial Statements (MDT)
|
|
|
|
Report date
|
|
|
30.04.2023 |
22.06.2023 |
30.04.2024 |
20.06.2024 |
20.06.2025 |
|
24.02.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
31 227 |
31 227 |
32 364 |
32 364 |
|
|
26 557 |
|
Operating Income, bln rub |
|
|
5 485 |
5 485 |
5 144 |
5 144 |
|
|
4 903 |
|
EBITDA, bln rub |
? |
|
8 697 |
8 475 |
8 203 |
9 056 |
|
|
7 081 |
|
Net profit, bln rub |
? |
|
3 758 |
3 758 |
3 676 |
3 676 |
|
|
3 557 |
|
|
OCF, bln rub |
? |
|
6 039 |
6 039 |
6 787 |
6 787 |
|
|
4 757 |
|
CAPEX, bln rub |
? |
|
1 459 |
1 459 |
1 587 |
1 587 |
|
|
1 416 |
|
FCF, bln rub |
? |
|
4 580 |
4 580 |
5 200 |
5 200 |
|
|
3 341 |
|
Dividend payout, bln rub
|
|
|
3 616 |
3 616 |
3 666 |
3 666 |
|
|
2 731 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
96.2% |
96.2% |
99.7% |
99.7% |
|
|
76.8% |
|
|
OPEX, bln rub |
|
|
15 023 |
14 678 |
16 004 |
16 129 |
|
|
11 299 |
|
Cost of production, bln rub |
|
|
10 719 |
10 719 |
11 216 |
12 911 |
|
|
10 354 |
|
R&D, bln rub |
|
|
2 696 |
2 696 |
2 735 |
2 735 |
|
|
2 202 |
|
Interest expenses, bln rub |
|
|
636.0 |
636.0 |
719.0 |
719.0 |
|
|
538.0 |
|
|
Assets, bln rub |
|
|
90 948 |
90 948 |
89 981 |
89 981 |
91 680 |
|
91 485 |
|
Net Assets, bln rub |
? |
|
51 483 |
51 483 |
50 214 |
50 214 |
48 024 |
|
48 985 |
|
Debt, bln rub |
|
|
24 364 |
24 364 |
25 024 |
25 024 |
28 516 |
|
28 071 |
|
Cash, bln rub |
|
|
7 959 |
7 959 |
8 005 |
8 005 |
8 965 |
|
8 383 |
|
Net debt, bln rub |
|
|
16 405 |
16 405 |
17 019 |
17 019 |
19 551 |
|
19 688 |
|
|
Ordinary share price, rub |
|
|
91.0 |
91.0 |
80.2 |
79.7 |
84.2 |
|
76.2 |
|
Number of ordinary shares, mln |
|
|
1 330 |
1 330 |
1 328 |
1 328 |
|
|
1 282 |
|
|
Market cap, bln rub |
|
|
120 945 |
120 945 |
106 535 |
105 871 |
0 |
|
97 632 |
|
EV, bln rub |
? |
|
137 350 |
137 350 |
123 554 |
122 890 |
19 551 |
|
117 320 |
|
Book value, bln rub |
|
|
-4 786 |
-4 786 |
9 228 |
-3 997 |
-5 380 |
|
-3 242 |
|
|
EPS, rub |
? |
|
2.83 |
2.83 |
2.77 |
2.77 |
|
|
2.77 |
|
FCF/share, rub |
|
|
3.44 |
3.44 |
3.92 |
3.92 |
|
|
2.61 |
|
BV/share, rub |
|
|
-3.60 |
-3.60 |
6.95 |
-3.01 |
|
|
-2.53 |
|
|
EBITDA margin, % |
? |
|
27.9% |
27.1% |
25.3% |
28.0% |
|
|
26.7% |
|
Net margin, % |
? |
|
12.0% |
12.0% |
11.4% |
11.4% |
|
|
13.4% |
|
FCF yield, % |
? |
|
3.79% |
3.79% |
4.88% |
4.91% |
0.00% |
|
3.42% |
|
ROE, % |
? |
|
7.30% |
7.30% |
7.32% |
7.32% |
0.00% |
|
7.26% |
|
ROA, % |
? |
|
4.13% |
4.13% |
4.09% |
4.09% |
0.00% |
|
3.89% |
|
|
P/E |
? |
|
32.2 |
32.2 |
29.0 |
28.8 |
|
|
27.4 |
|
P/FCF |
|
|
26.4 |
26.4 |
20.5 |
20.4 |
|
|
29.2 |
|
P/S |
? |
|
3.87 |
3.87 |
3.29 |
3.27 |
|
|
3.68 |
|
P/BV |
? |
|
-25.3 |
-25.3 |
11.5 |
-26.5 |
0.00 |
|
-30.1 |
|
EV/EBITDA |
? |
|
15.8 |
16.2 |
15.1 |
13.6 |
|
|
16.6 |
|
Debt/EBITDA |
|
|
1.89 |
1.94 |
2.07 |
1.88 |
|
|
2.78 |
|
|
R&D/CAPEX, % |
|
|
184.8% |
184.8% |
172.3% |
172.3% |
|
|
155.5% |
|
|
CAPEX/Revenue, % |
|
|
4.67% |
4.67% |
4.90% |
4.90% |
|
|
5.33% |
|
| Medtronic shareholders |
